(Q38001377)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

A prospective model of care for breast cancer rehabilitation: bone health and arthralgias (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

5

Kristin L Campbell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Kerri M Winters-Stone

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Anna L Schwartz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Carol J Fabian

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

8 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

2288-2299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Clinical review: Effect of endocrine therapies on bone in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Cancer treatment-induced bone loss in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Changes in weight and body composition in women receiving chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Aromatase inhibitor-associated arthralgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

American College of Sports Medicine roundtable on exercise guidelines for cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The prevalence of symptoms possibly related to the climacteric in pre- and postmenopausal women in Linköping, Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

New views on treatment of aromatase inhibitors induced arthralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Immune responses and bone loss: the estrogen connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Modulation of pain by estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Peripheral estradiol induces temporomandibular joint antinociception in rats by activating the nitric oxide/cyclic guanosine monophosphate signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Rheumatic disorders and functional disability with aromatase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The use of Nolvadex in the treatment of generic Tamoxifen-associated small joint arthralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Pharmacology of arthralgia with estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Managing the toxicities of the aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Effectively nursing patients receiving aromatase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Managing aromatase inhibitors in breast cancer survivors: not just for oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Assessment of fracture risk in women with breast cancer using current vs emerging guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

NCCN Task Force Report: Bone Health in Cancer Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone Health and Falls: Fracture Risk in Breast Cancer Survivors With Chemotherapy-Induced Amenorrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Excess mortality following hip fracture: a systematic epidemiological review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Mortality rates after incident non-traumatic fractures in older men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Exemestane for breast-cancer prevention in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Diagnosis of osteoporosis and assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Femoral Bone Mineral Density, Neck-Shaft Angle and Mean Femoral Neck Width as Predictors of Hip Fracture in Men and Women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Quantitative ultrasound: an indicator of osteoporosis in perimenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Screening for osteoporosis: U.S. preventive services task force recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

American College of Sports Medicine Position Stand: physical activity and bone health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Meta-analysis of walking for preservation of bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

High-intensity resistance training and postmenopausal bone loss: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Progressive high-intensity resistance training and bone mineral density changes among premenopausal women: evidence of discordant site-specific skeletal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

A review of exercise interventions to improve bone health in adult cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Effects of a one-year high-intensity versus low-intensity resistance training program on bone mineral density in older women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

American College of Sports Medicine position stand. Progression models in resistance training for healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Site-specific response of bone to exercise in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Exercise improves body fat, lean mass, and bone mass in breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

A randomized trial to increase physical activity in breast cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Meta-analysis of the effectiveness of physical activity for the prevention of bone loss in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Aerobic exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Should future risk-of-fracture analyses include another major risk factor? The case for falls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Summary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Tai Chi and falls prevention in older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

Estrogen receptor-beta is the predominant estrogen receptor subtype in normal human synovia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Health behaviors in breast cancer survivors experiencing bone loss

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Bone mineral density and adjuvant therapy in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Bone mineral density in postmenopausal breast cancer survivors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Breast cancer and bone mineral density: the Marburg Breast Cancer and Osteoporosis Trial (MABOT II)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Effect of menopause on femoral and vertebral bone loss

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Ultrasound and densitometry of the calcaneus correlate with the failure loads of cadaveric femurs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Bone strength at clinically relevant sites displays substantial heterogeneity and is best predicted from site-specific bone densitometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Femoral bone mineral density, neck-shaft angle and mean femoral neck width as predictors of hip fracture in men and women. Multicenter Project for Research in Osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Aerobic exercise and bone density at the hip in postmenopausal women: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27465

7 January 2021

Identifiers

DOI

10.1002/CNCR.27465

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488703%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference